Literature DB >> 11682630

Critical residues for the specificity of cofactors and substrates in human estrogenic 17beta-hydroxysteroid dehydrogenase 1: variants designed from the three-dimensional structure of the enzyme.

Y W Huang1, I Pineau, H J Chang, A Azzi, V Bellemare, S Laberge, S X Lin.   

Abstract

Human estrogenic 17beta-hydroxysteroid dehydrogenase is an NADP(H)-preferring enzyme. It possesses 11- and 4-fold higher specificity toward NADP(H) over NAD(H) for oxidation and reduction, respectively, as demonstrated by kinetic studies. To elucidate the roles of the amino acids involved in cofactor specificity, we generated variants by site-directed mutagenesis. The results showed that introducing a positively charged residue, lysine, at the Ser12 position increased the enzyme's preference for NADP(H) more than 20-fold. Substitution of the negatively charged residue, aspartic acid, into the Leu36 position switched the enzyme's cofactor preference from NADPH to NAD with a 220-fold change in the ratio of the specificity toward the two cofactors in the case of oxidation. This variant dramatically abolished the enzyme's reductase function and stimulated its dehydrogenase activity, as shown by enzyme activity in intact cells. The substrate-binding pocket was also studied with four variants: Ser142Gly, Ser142Cys, His221Ala, and Glu282Ala. The Ser142Gly variant abolished most of the enzyme's oxidation and reduction activities. The residual reductase activity in vitro is less than 2% that of the wild-type enzyme. However, the Ser142Cys variant was fully inactive, both as a partially purified protein and in intact cells. This suggests that the bulky sulfhydryl group of cysteine entirely disrupted the catalytic triad and that the Ser142 side chain is important for maintaining the integrity of this triad. His221 variation weakened the apparent affinity for estrone, as demonstrated by a 30-fold increase in Michaelis-Menten constant, supporting its important role in substrate binding. This residue may play an important role in substrate inhibition via the formation of a dead-end complex. The formerly suggested importance of Glu282 could not be confirmed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11682630     DOI: 10.1210/mend.15.11.0730

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  15 in total

1.  Lipid-mediated unfolding of 3β-hydroxysteroid dehydrogenase 2 is essential for steroidogenic activity.

Authors:  Maheshinie Rajapaksha; James L Thomas; Michael Streeter; Manoj Prasad; Randy M Whittal; John D Bell; Himangshu S Bose
Journal:  Biochemistry       Date:  2011-12-06       Impact factor: 3.162

2.  17beta-hydroxysteroid dehydrogenase type 1 stimulates breast cancer by dihydrotestosterone inactivation in addition to estradiol production.

Authors:  Juliette A Aka; Mausumi Mazumdar; Chang-Qing Chen; Donald Poirier; Sheng-Xiang Lin
Journal:  Mol Endocrinol       Date:  2010-02-19

3.  Molecular modeling and site-directed mutagenesis reveal the benzylisoquinoline binding site of the short-chain dehydrogenase/reductase salutaridine reductase.

Authors:  René Geissler; Wolfgang Brandt; Jörg Ziegler
Journal:  Plant Physiol       Date:  2007-03-02       Impact factor: 8.340

4.  Homology modeling and site-directed mutagenesis reveal catalytic key amino acids of 3beta-hydroxysteroid-dehydrogenase/C4-decarboxylase from Arabidopsis.

Authors:  Alain Rahier; Marc Bergdoll; Geneviève Génot; Florence Bouvier; Bilal Camara
Journal:  Plant Physiol       Date:  2009-02-13       Impact factor: 8.340

5.  Species used for drug testing reveal different inhibition susceptibility for 17beta-hydroxysteroid dehydrogenase type 1.

Authors:  Gabriele Möller; Bettina Husen; Dorota Kowalik; Leena Hirvelä; Dariusz Plewczynski; Leszek Rychlewski; Josef Messinger; Hubert Thole; Jerzy Adamski
Journal:  PLoS One       Date:  2010-06-08       Impact factor: 3.240

6.  Management of the adult with congenital adrenal hyperplasia.

Authors:  Richard J Auchus
Journal:  Int J Pediatr Endocrinol       Date:  2010-05-30

7.  Engineering cofactor preference of ketone reducing biocatalysts: A mutagenesis study on a γ-diketone reductase from the yeast Saccharomyces cerevisiae serving as an example.

Authors:  Michael Katzberg; Nàdia Skorupa-Parachin; Marie-Françoise Gorwa-Grauslund; Martin Bertau
Journal:  Int J Mol Sci       Date:  2010-04-14       Impact factor: 5.923

8.  Characterization of key residues and membrane association domains in retinol dehydrogenase 10.

Authors:  Yusuke Takahashi; Gennadiy Moiseyev; Krysten Farjo; Jian-Xing Ma
Journal:  Biochem J       Date:  2009-04-01       Impact factor: 3.857

9.  Characterization of essential domains in HSD17B13 for cellular localization and enzymatic activity.

Authors:  Yanling Ma; Suman Karki; Philip M Brown; Dennis D Lin; Maren C Podszun; Wenchang Zhou; Olga V Belyaeva; Natalia Y Kedishvili; Yaron Rotman
Journal:  J Lipid Res       Date:  2020-09-24       Impact factor: 5.922

10.  Biochemical factors governing the steady-state estrone/estradiol ratios catalyzed by human 17beta-hydroxysteroid dehydrogenases types 1 and 2 in HEK-293 cells.

Authors:  Daniel P Sherbet; Oleg L Guryev; Mahboubeh Papari-Zareei; Dario Mizrachi; Siayareh Rambally; Sharareh Akbar; Richard J Auchus
Journal:  Endocrinology       Date:  2009-06-25       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.